This is a prospective, phase 2, multicenter clinical trial study to compare the efficacy and safety of using prednisone in combination with IVIg compared to using just prednisone as a monotherapy in the treatment of immune thrombocytopenia (ITP) in pregnancy. Eligibility is restricted to individuals with a platelet count less than 30,000, confirmed to be pregnant (at least 12 weeks along in the pregnancy) with confirmed ITP between the ages of 18-50 years.
Platelet count, bleeding and other symptoms will be evaluated before and after treatment. Time to response and platelet counts of newborns will also be recorded, and any adverse events will be recorded throughout and after the study.
China
Status: Actively Recruiting